ZAP70
- Known as:
- ZAP70
- Catalog number:
- NB100-92241
- Product Quantity:
- 0.1 mg
- Category:
- -
- Supplier:
- ACR
- Gene target:
- ZAP70
Related genes to: ZAP70
- Gene:
- ZAP70 NIH gene
- Name:
- zeta chain of T cell receptor associated protein kinase 70
- Previous symbol:
- SRK
- Synonyms:
- ZAP-70, STD
- Chromosome:
- 2q11.2
- Locus Type:
- gene with protein product
- Date approved:
- 1995-05-16
- Date modifiied:
- 2019-04-23
Related products to: ZAP70
70 kDa zeta-associated protein,Homo sapiens,Human,SRK,Syk-related tyrosine kinase,Tyrosine-protein kinase ZAP-70,ZAP7070 kDa zeta-associated protein,Mouse,Mus musculus,Srk,Syk-related tyrosine kinase,Tyrosine-protein kinase ZAP-70,Zap70,Zap-70Active ZAP70Active ZAP70anti-ZAP70anti-ZAP70anti-ZAP70anti-ZAP70 (2F6)anti-ZAP70 (11H40)anti-ZAP70 (11H40)anti-ZAP70 (11H40) type: Primary antibodies host: MouseAnti-ZAP70 (11H40), Mouse Monoclonal to ZAP70, Isotype , Host Mouseanti-ZAP70 (2F6)anti-ZAP70 (3D2A4)anti-ZAP70 (49B4) Related articles to: ZAP70
- This study examines sulfamethoxazole (SMX), a sulfonamide antibiotic strongly associated with severe cutaneous adverse effects, as a potential regulator of invariant natural killer T (iNKT) cells. This work combines molecular docking (to evaluate the likelihood of SMX binding to residues within a conventional binding pocket), molecular dynamics (to assess the stability of SMX binding and the forces that may destabilize the interaction), flow cytometry (to evaluate iNKT-cell activation in the presence of SMX within the context of established antigen presentation models), and particularly Raman spectroscopy (to investigate whether SMX-associated spectral features are retained after co-incubation and interaction) directly on sorted iNKT cells. Functional activation was assessed through IFN-γ production from sorted iNKT cells and correlated with Raman spectral data to support our hypothesis. The Raman spectroscopy was performed on both CD1d dimer (in isolation) as the presenter molecule of the drug and in sorted iNKT cells (in isolation), to identify spectroscopic evidence of drug-CD1dimer or drug-cell interactions under near-physiological conditions. From the CD1d experiment, we observed spectral features consistent with potential interactions between CD1d and serum-derived lipids, in a manner comparable to the positive control (α-GalCer). From the iNKT experiment, peaks at 1610 and 1663 cm-1 are the representative peaks that emerge under SMX stimulation conditions in iNKT cells (through TCR binding), as identified by second principal component (PC2) analysis. From the complete experiment, (CD1d + iNKT) suggests the possibility of a direct interaction between SMX and iNKT TCRs. Flow cytometry analysis further demonstrated a significant increase in ZAP-70 phosphorylation in sorted iNKT cells exposed to SMX under serum-free conditions, supporting the possibility of proximal TCR-associated signaling in the absence of CD1d. - Source: PubMed
Hernández-Jaimes O AZárate-Reyes J MLópez-Luis M AOrtiz-Sánchez EGallardo-Hernández S - TRAIL is a TNF family ligand that trimerizes TRAIL-R1 (DR4) or TRAIL-R2 (DR5) to induce apoptosis, necroptosis, and/or NF-κB activation in receptor-bearing cells. We previously identified TRAILshort as a splice variant of TRAIL that lacks cysteine 230, cannot trimerize, and acts as a dominant-negative ligand that blocks TRAIL-mediated apoptosis. TRAILshort is expressed on cell surfaces and within extracellular vesicles, enabling it to confer TRAIL resistance to both producing and bystander cells. In this study, we showed that elevated TRAILshort levels were associated with chronic viral infections, cancer, and autoimmune diseases, suggesting a link to impaired immune regulation. Using unbiased phosphoproteomics and mechanistic studies, we demonstrated that TRAILshort binding to DR5 recruited and activated the phosphatase Src homology region 2 domain-containing phosphatase 1 (SHP-1), leading to zeta-chain-associated protein kinase 70 (ZAP-70) dephosphorylation, disruption of ZAP-70-CD3ζ interactions, and impaired T cell receptor signaling, thereby reducing T cell activation, proliferation, and cytokine production in response to antigen or CD3/CD28 ligation. Genetic or pharmacologic SHP-1 inhibition reverses these effects. In humanized mouse models, TRAILshort promoted the persistence of transformed mouse embryonic fibroblasts (MEFs) and L428 and antagonized CD19-directed CAR T cell activity, revealing TRAILshort as an immunomodulator of T cell function with therapeutic implications, including blocking TRAILshort to restore T cell immunity or delivering TRAILshort to enforce tolerance. - Source: PubMed
Publication date: 2026/08/03
Jalali ShahrzadNatesampillai SekarNie ZilinZhang YingCan IsmailChandrasekar Aswath PHameister Brianna MCorreia CristinaZhao Tuantuan VMun Dong-GiGarcia-Rivera EnriqueMatson RobertKrogman AshtonMaynes Mark ABatchelor RobinMonie Dileep DLi HuBehfar AttaKenderian Saad SPandey AkhileshAnsell Stephen MTaner TimucinWeyand CorneliaBilladeau Daniel DBadley Andrew D - Cytotoxic T lymphocytes (CTLs) play a pivotal role in antitumor immunity via inducing apoptosis in cancer cells. However, their effector functions can be compromised by the perturbations in the tumor microenvironment (TME). Among the diverse factors within the TME, the effects of stiffness of the extracellular matrix (ECM) on CTL-mediated responses require greater understanding. To address this gap, we three-dimensionally bioprinted CTLs and targeted cells in polyethylene glycol-based ECM mimics with tunable stiffness and uniform porosity. Our findings reveal that CTLs in stiffer ECMs showed reduced migration speed and impaired antigen-specific cytotoxicity. Synapse formation analysis revealed that stiffer ECMs impair CTL efficacy not by reducing the frequency of CTL-target cell contacts but by shortening the contact time between these cells, a consequence of disrupted immunological synapse formation. Live Ca imaging and expression of phospho-ZAP70 confirmed these findings. Together, these results suggest that ECM stiffness modulates CTL function at multiple levels, from migration to cytotoxicity and synapse quality. - Source: PubMed
Publication date: 2026/07/31
Seyedzadeh Mir HadiTolentino MA KristineGil Peres NewtonDu Eric YBartlett-Tomasetig FlorenceJavier Gaia M NKilian Kristopher AGaus KatharinaGoyette JesseGooding J Justin - As a chronic relapsing immune-mediated skin disorder, psoriasis is mainly driven by CD8 T cells during disease progression, while the molecular basis of CD8 T cell recruitment and activation in psoriatic lesions remains largely unclear, and the function of CEACAM5 in psoriasis remains uncharacterized. Here, we report that CEACAM5 is significantly upregulated in psoriatic patient epidermal lesions and M5-induced psoriatic keratinocytes in vitro. CEACAM5 knockdown prominently inhibits chemokine expression in keratinocytes, attenuates CD8 T cell recruitment, and downregulates pro-inflammatory cytokine production in recruited CD8 T cells. Mechanistic studies reveal that soluble CEACAM5 directly activates the Lck/ZAP70 signaling axis to promote the inflammatory activation of CD8 T cells. Collectively, our work identifies CEACAM5 as a critical regulator of CD8 T cell responses in psoriasis, providing a novel potential therapeutic target for this disease. - Source: PubMed
Publication date: 2026/07/15
Wang LifengLiu XiaotaoCao KainaLiu YifeiLiang SurongXu LijuanXu Zigang - Cholangiocarcinoma (CCA) has a complex tumor microenvironment (TME) and poor immunotherapy response. Understanding how the adaptive immune response (AIR) affects the TME and prognosis is critical. - Source: PubMed
Publication date: 2026/07/06
Jie WangJixiang ZhouYang BaoYanting WangLing Liu